Recent Company News

• 09:46 PM ET Jul 02, 2026
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 08:05 AM ET Jun 30, 2026
  

  U.S. Renal Care and Akebia interim analysis of VOICE Trial demonstrated improved safety outcomes for patients treated with Vafseo versus an ESA ($1.11, 0.00)

• 07:42 PM ET Jun 28, 2026
  

  EMA recommends revoking EU marketing authorisation for CSL's TAVNEOS (avacopan) (A$114.87, 0.00)

• 09:04 AM ET Jun 26, 2026
  

  CHMP recommends revoking marketing authorisation for TAVNEOS (avacopan) in the European Union (A$114.87, 0.00)

• 09:00 AM ET Jun 26, 2026
  

  CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

• 08:51 AM ET Jun 26, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:34 AM ET Jun 26, 2026
  

  EMA CHMP publishes summary of opinions for June 2026 meeting

• 06:57 AM ET Jun 26, 2026
  

  EU's CHMP adopted a positive opinion recommending the granting of a marketing authorisation for Aujemflu (A$114.87, 0.00)

• 06:07 AM ET Jun 26, 2026
  

  EU Commission opens investigation into possible anticompetitive conduct by Sanofi regarding the promotion of a flu vaccine for vulnerable patients (€74.03, +0.27)